Single-Dose Relative Bioavailability of a New Quetiapine Fumarate Extended-Release Formulation: A Postprandial, Randomized, Open-Label, Two-Period Crossover Study in Healthy Uruguayan Volunteers

Clinical Therapeutics

Volumn 33, Issue 6, 2011, Pages 738-745

  Estevez Carrizo, Francisco E ^a,b   Parrillo, Susana ^a,b   Ercoli, Mónica Cedres ^a   Estevez Parrillo, Francisco T ^a  

^a Center for Clinical Pharmacology Research   (Uruguay)

^b UNIVERSIDAD DE MONTEVIDEO   (Uruguay)

Author keywords

Bioequivalence; Bipolar disorder pharmacokinetics; Quetiapine xR; Schizophrenia

Indexed keywords

QUETIA; QUETIAPINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARITHMETIC; ARTICLE; AUTHORITY; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD SAMPLING; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; FEMALE; HEADACHE; HEIGHT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; LABORATORY TEST; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; MONITORING; NAUSEA; NORMAL HUMAN; PALLOR; PLASMA CONCENTRATION-TIME CURVE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; URUGUAY; VITAL SIGN; VOMITING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DIETARY FATS; FEMALE; HUMANS; MALE; POSTPRANDIAL PERIOD; TABLETS; THERAPEUTIC EQUIVALENCY; URUGUAY; YOUNG ADULT;

EID: 79959475689     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.05.002     Document Type: Article

References (23)

1. Peuskens J., Trivedy J.K., Brecher M., Miller F. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. Int Clin Psychopharmacol 2010, 25:183-187.
2. Meulien D., Huizar K., Brechner M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010, 25:103-115.
3. Al Jurdi R.K., Dixit L.A., Satajovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat 2010, 6:29-35.
4. McIntyre R.S., Muzina D.J., Adams A., et al. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. Expert Opin Pharmacother 2009, 10:3061-3075.
5. Bauer M., Pretorius H.W., Constant E.L., et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009, 70:540-549.
6. Jensen N.H., Rodriguez R., Caron M.G., et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
7. DeVane C.L., Nemeroff C.B. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001, 40:509-522.
8. Seroquel (quetiapine fumarate) tablets. Label Accessed May 24, 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20639se1-017,016_seroquel_lbl.pdf.
9. McIntyre R.S., Soczynzka J.K., Woldeyohannes H.O., et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007, 8:1211-1219.
10. Bakken G.V., Rudberg I., Christensen H., et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Met Disp 2009, 37:254-258.
11. Figueroa C., Brecher M., Hamer-Maansson J.E., Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:199-204.
12. Baldwin C.M., Scott L.J. Quetiapine extended release: in schizophrenia. CNS Drugs 2009, 23:261-269.
13. Recomendaciones técnicas para la realización de estudios de bioequivalencia. Anexos, I, II y III. Decreto N° 12/2007, Ministerio de Salud Pública, República Oriental del Uruguay. Passed: 01/12/2007; Issued: 01/22/2007. Registro Nacional de Leyes y Decretos: Tomo 1; Semestre 1; Año 2007, Página 103.
14. Diletti E., Hauschke D., Steinijans W. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1992, 30(Suppl 1):S59-S62.
15. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations March 2003, US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research CDER, Accessed May 24, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.
16. Hasselstrøm J., Linnet K. Fully automated on-line quantification of quetiapine in human serum by solid phase extraction and liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 798:9-16.
17. Guidance for Industry. Bionalytical Method Validation May 2001, US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM), Accessed April 8, 2009. http://www.fda.gov/cder/guidance/4252fnl.html.
18. Assessment of average bioequivalence in the RT/TR design. Bioequivalence Studies in Drug Development. Methods and Applications 2007, 69-104. John Wiley & Sons, Ltd, New York, NY. D. Hauschke, V. Steinijans, I. Pigeot (Eds.).
19. Sauter R., Steinijans V.W., Diletti E., et al. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992, 30(Suppl 1):S7-S30.
20. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987, 15:657-680.
21. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence January 2001, US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), Accessed May 24, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf.
22. Mahatthhanatrakul K., Rattana S., Sriwiriyajan S., et al. Bioequivalence study of a generic quetiapine in healthy male volunteers. Int J Clin Pharmacol Ther 2008, 46:489-496.
23. Datto C., Berggren L., Patel J.B., Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009, 31:492-502.